Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

213 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: the Resistance and Dosage Adapted Regimens (RADAR) study.
Torti C, Quiros-Roldan E, Regazzi M, De Luca A, Mazzotta F, Antinori A, Ladisa N, Micheli V, Orani A, Patroni A, Villani P, Lo Caputo S, Moretti F, Di Giambenedetto S, Castelnuovo F, Maggi P, Tinelli C, Carosi G; RADAR-MASTER Study Group. Torti C, et al. Among authors: lo caputo s. Clin Infect Dis. 2005 Jun 15;40(12):1828-36. doi: 10.1086/429917. Epub 2005 May 12. Clin Infect Dis. 2005. PMID: 15909273 Clinical Trial.
Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection.
Ammassari A, Murri R, Pezzotti P, Trotta MP, Ravasio L, De Longis P, Lo Caputo S, Narciso P, Pauluzzi S, Carosi G, Nappa S, Piano P, Izzo CM, Lichtner M, Rezza G, Monforte A, Ippolito G, d'Arminio Moroni M, Wu AW, Antinori A; AdICONA Study Group. Ammassari A, et al. Among authors: lo caputo s. J Acquir Immune Defic Syndr. 2001 Dec 15;28(5):445-9. doi: 10.1097/00042560-200112150-00006. J Acquir Immune Defic Syndr. 2001. PMID: 11744832
Modulation of human immunodeficiency virus (HIV)-specific immune response by using efavirenz, nelfinavir, and stavudine in a rescue therapy regimen for HIV-infected, drug-experienced patients.
Trabattoni D, Lo Caputo S, Biasin M, Seminari E, Di Pietro M, Ravasi G, Mazzotta F, Maserati R, Clerici M. Trabattoni D, et al. Among authors: lo caputo s. Clin Diagn Lab Immunol. 2002 Sep;9(5):1114-8. doi: 10.1128/cdli.9.5.1114-1118.2002. Clin Diagn Lab Immunol. 2002. PMID: 12204968 Free PMC article. Clinical Trial.
Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48-week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) trial.
Mazzotta F, Lo Caputo S, Torti C, Tinelli C, Pierotti P, Castelli F, Lazzarin A, Angarano G, Maserati R, Gianotti N, Ladisa N, Quiros-Roldan E, Rinehart AR, Carosi G; Genotipo-Fenotipo di Resistenza (GenPheRex) Group of the Italian Management Standardizzato di Terapia Antiretrovirale (MASTER) Cohort. Mazzotta F, et al. Among authors: lo caputo s. J Acquir Immune Defic Syndr. 2003 Mar 1;32(3):268-80. doi: 10.1097/00126334-200303010-00005. J Acquir Immune Defic Syndr. 2003. PMID: 12626886 Clinical Trial.
Comparison between rules-based human immunodeficiency virus type 1 genotype interpretations and real or virtual phenotype: concordance analysis and correlation with clinical outcome in heavily treated patients.
Torti C, Quiros-Roldan E, Keulen W, Scudeller L, Lo Caputo S, Boucher C, Castelli F, Mazzotta F, Pierotti P, Been-Tiktak AM, Buccoliero G, De Gennaro M, Carosi G, Tinelli C; GenPherex Study Group of the MaSTeR Cohort. Torti C, et al. Among authors: lo caputo s. J Infect Dis. 2003 Jul 15;188(2):194-201. doi: 10.1086/376512. Epub 2003 Jul 1. J Infect Dis. 2003. PMID: 12854073
Characterization of viro-immunological responses in a closely followed cohort of heavily pretreated patients: evidence from the GenPheRex Study.
Torti C, Quiros-Roldan E, Scudeller L, Lo Caputo S, Tomasoni L, Castelli F, Poggio A, Delle Foglie P, Chirianni A, Sighinolfi L, Mazzotta F, Carosi G; GenPheRex Group of the Ma.S.Te.R. Cohort. Torti C, et al. Among authors: lo caputo s. HIV Med. 2003 Jul;4(3):263-70. doi: 10.1046/j.1468-1293.2003.00154.x. HIV Med. 2003. PMID: 12859326 Free article. Clinical Trial.
HIV susceptibility to amprenavir: phenotype-based versus rules-based interpretations.
Scudeller L, Torti C, Quiros-Roldan E, Patroni A, Lo Caputo S, Moretti F, Mazzotta F, Donati E, Vivarelli A, Carosi G; GenPheRex Group of the MASTER Cohort. Scudeller L, et al. Among authors: lo caputo s. J Antimicrob Chemother. 2003 Nov;52(5):776-81. doi: 10.1093/jac/dkg456. Epub 2003 Oct 16. J Antimicrob Chemother. 2003. PMID: 14563897 Clinical Trial.
Lipid abnormalities in HIV-infected patients are not correlated with lopinavir plasma concentrations.
Torti C, Quiros-Roldan E, Regazzi-Bonora M, De Luca A, Lo Caputo S, Di Giambenedetto S, Patroni A, Villani P, Micheli V, Carosi G; Resistance and Dosage Adapted Regimens Study Group of the MASTER Cohort. Torti C, et al. Among authors: lo caputo s. J Acquir Immune Defic Syndr. 2004 Mar 1;35(3):324-6. doi: 10.1097/00126334-200403010-00017. J Acquir Immune Defic Syndr. 2004. PMID: 15076251 Clinical Trial. No abstract available.
213 results